ReShape Lifesciences Dividends
| RSLS Stock | USD 5.56 0.19 3.30% |
Dividend Paid And Capex Coverage Ratio is likely to drop to -414.14 in 2024. ReShape Lifesciences' past performance could be the main factor of why investors trade ReShape Lifesciences stock today. Investors should clearly understand every aspect of the ReShape Lifesciences dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest ReShape Lifesciences' dividend schedule and payout information. ReShape Lifesciences dividends can also provide a clue to the current valuation of ReShape Lifesciences.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (394.42) | (414.14) |
ReShape |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in ReShape Lifesciences must own a stock before its ex-dividend date to receive its next dividend.
ReShape Lifesciences Dividends Paid Over Time
Today, most investors in ReShape Lifesciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ReShape Lifesciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ReShape Lifesciences dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 76.2 | Revenue Per Share 27.638 | Quarterly Revenue Growth (0.13) | Return On Assets (0.63) | Return On Equity (1.85) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.